Inhibition of intracranial glioma growth by endometrial regenerative cells

Xiaodi Han, Xiaolong Meng, Zhenglian Yin, Andrea Rogers, Jie Zhong, Paul Rillema, James A. Jackson, Thomas E. Ichim, Boris Minev, Ewa Carrier, Amit N. Patel, Michael Murphy, Wei Ping Min, Neil H. Riordan

Research output: Contribution to journalArticle

38 Citations (Scopus)

Abstract

Animal studies have demonstrated that selective tropism of mesenchymal stem cells (MSC) for glioma may be used as a means of selective delivery of cytotoxic payloads. Endometrial Regenerative Cells (ERC) are a population of mesenchymal-like cells which possesse pluripotent differentiation capacity and is characterized by unique surface markers and growth factor production. In this study we sought to determine whether unmanipulated ERC would alter the growth of glioma using the aggressive C6/ LacZ7 (C6) into Sprague Dawley rat model. ERC administration by intravenous (i.v.) or intratumoral (i.t.) showed significant inhibition of glioma: volume reduction of 49% after i.v. treatment (p < 0.05), and about 46% i.t. treatment (p < 0.05). Tumor reduction was associated with inhibition of angiogenesis and reduced numbers of CD133 positive cells in the incranial tumor. Despite the angiogenic potential of ERC in the hindlimb ischemia model, these data support a paradoxical tumor inhibitory activity of ERC. Further studies are needed to determine the qualitative differences between physiological angiogenesis, which seems to be supported by ERC and tumor angiogenesis which appeared to be inhibited.

Original languageEnglish
Pages (from-to)606-610
Number of pages5
JournalCell Cycle
Volume8
Issue number4
StatePublished - Feb 15 2009

Fingerprint

Glioma
Growth
Neoplasms
Physiologic Neovascularization
Tropism
Hindlimb
Mesenchymal Stromal Cells
Intravenous Administration
Sprague Dawley Rats
Intercellular Signaling Peptides and Proteins
Ischemia
Therapeutics
Population

Keywords

  • Cancer stem cells
  • Endometrial regenerative cells
  • Glioma
  • Immune
  • Mesenchymal stem cells
  • Stem cell therapy

ASJC Scopus subject areas

  • Cell Biology
  • Molecular Biology
  • Developmental Biology

Cite this

Han, X., Meng, X., Yin, Z., Rogers, A., Zhong, J., Rillema, P., ... Riordan, N. H. (2009). Inhibition of intracranial glioma growth by endometrial regenerative cells. Cell Cycle, 8(4), 606-610.

Inhibition of intracranial glioma growth by endometrial regenerative cells. / Han, Xiaodi; Meng, Xiaolong; Yin, Zhenglian; Rogers, Andrea; Zhong, Jie; Rillema, Paul; Jackson, James A.; Ichim, Thomas E.; Minev, Boris; Carrier, Ewa; Patel, Amit N.; Murphy, Michael; Min, Wei Ping; Riordan, Neil H.

In: Cell Cycle, Vol. 8, No. 4, 15.02.2009, p. 606-610.

Research output: Contribution to journalArticle

Han, X, Meng, X, Yin, Z, Rogers, A, Zhong, J, Rillema, P, Jackson, JA, Ichim, TE, Minev, B, Carrier, E, Patel, AN, Murphy, M, Min, WP & Riordan, NH 2009, 'Inhibition of intracranial glioma growth by endometrial regenerative cells', Cell Cycle, vol. 8, no. 4, pp. 606-610.
Han X, Meng X, Yin Z, Rogers A, Zhong J, Rillema P et al. Inhibition of intracranial glioma growth by endometrial regenerative cells. Cell Cycle. 2009 Feb 15;8(4):606-610.
Han, Xiaodi ; Meng, Xiaolong ; Yin, Zhenglian ; Rogers, Andrea ; Zhong, Jie ; Rillema, Paul ; Jackson, James A. ; Ichim, Thomas E. ; Minev, Boris ; Carrier, Ewa ; Patel, Amit N. ; Murphy, Michael ; Min, Wei Ping ; Riordan, Neil H. / Inhibition of intracranial glioma growth by endometrial regenerative cells. In: Cell Cycle. 2009 ; Vol. 8, No. 4. pp. 606-610.
@article{b31af1b04518425699cf14604b6bf09f,
title = "Inhibition of intracranial glioma growth by endometrial regenerative cells",
abstract = "Animal studies have demonstrated that selective tropism of mesenchymal stem cells (MSC) for glioma may be used as a means of selective delivery of cytotoxic payloads. Endometrial Regenerative Cells (ERC) are a population of mesenchymal-like cells which possesse pluripotent differentiation capacity and is characterized by unique surface markers and growth factor production. In this study we sought to determine whether unmanipulated ERC would alter the growth of glioma using the aggressive C6/ LacZ7 (C6) into Sprague Dawley rat model. ERC administration by intravenous (i.v.) or intratumoral (i.t.) showed significant inhibition of glioma: volume reduction of 49{\%} after i.v. treatment (p < 0.05), and about 46{\%} i.t. treatment (p < 0.05). Tumor reduction was associated with inhibition of angiogenesis and reduced numbers of CD133 positive cells in the incranial tumor. Despite the angiogenic potential of ERC in the hindlimb ischemia model, these data support a paradoxical tumor inhibitory activity of ERC. Further studies are needed to determine the qualitative differences between physiological angiogenesis, which seems to be supported by ERC and tumor angiogenesis which appeared to be inhibited.",
keywords = "Cancer stem cells, Endometrial regenerative cells, Glioma, Immune, Mesenchymal stem cells, Stem cell therapy",
author = "Xiaodi Han and Xiaolong Meng and Zhenglian Yin and Andrea Rogers and Jie Zhong and Paul Rillema and Jackson, {James A.} and Ichim, {Thomas E.} and Boris Minev and Ewa Carrier and Patel, {Amit N.} and Michael Murphy and Min, {Wei Ping} and Riordan, {Neil H.}",
year = "2009",
month = "2",
day = "15",
language = "English",
volume = "8",
pages = "606--610",
journal = "Cell Cycle",
issn = "1538-4101",
publisher = "Landes Bioscience",
number = "4",

}

TY - JOUR

T1 - Inhibition of intracranial glioma growth by endometrial regenerative cells

AU - Han, Xiaodi

AU - Meng, Xiaolong

AU - Yin, Zhenglian

AU - Rogers, Andrea

AU - Zhong, Jie

AU - Rillema, Paul

AU - Jackson, James A.

AU - Ichim, Thomas E.

AU - Minev, Boris

AU - Carrier, Ewa

AU - Patel, Amit N.

AU - Murphy, Michael

AU - Min, Wei Ping

AU - Riordan, Neil H.

PY - 2009/2/15

Y1 - 2009/2/15

N2 - Animal studies have demonstrated that selective tropism of mesenchymal stem cells (MSC) for glioma may be used as a means of selective delivery of cytotoxic payloads. Endometrial Regenerative Cells (ERC) are a population of mesenchymal-like cells which possesse pluripotent differentiation capacity and is characterized by unique surface markers and growth factor production. In this study we sought to determine whether unmanipulated ERC would alter the growth of glioma using the aggressive C6/ LacZ7 (C6) into Sprague Dawley rat model. ERC administration by intravenous (i.v.) or intratumoral (i.t.) showed significant inhibition of glioma: volume reduction of 49% after i.v. treatment (p < 0.05), and about 46% i.t. treatment (p < 0.05). Tumor reduction was associated with inhibition of angiogenesis and reduced numbers of CD133 positive cells in the incranial tumor. Despite the angiogenic potential of ERC in the hindlimb ischemia model, these data support a paradoxical tumor inhibitory activity of ERC. Further studies are needed to determine the qualitative differences between physiological angiogenesis, which seems to be supported by ERC and tumor angiogenesis which appeared to be inhibited.

AB - Animal studies have demonstrated that selective tropism of mesenchymal stem cells (MSC) for glioma may be used as a means of selective delivery of cytotoxic payloads. Endometrial Regenerative Cells (ERC) are a population of mesenchymal-like cells which possesse pluripotent differentiation capacity and is characterized by unique surface markers and growth factor production. In this study we sought to determine whether unmanipulated ERC would alter the growth of glioma using the aggressive C6/ LacZ7 (C6) into Sprague Dawley rat model. ERC administration by intravenous (i.v.) or intratumoral (i.t.) showed significant inhibition of glioma: volume reduction of 49% after i.v. treatment (p < 0.05), and about 46% i.t. treatment (p < 0.05). Tumor reduction was associated with inhibition of angiogenesis and reduced numbers of CD133 positive cells in the incranial tumor. Despite the angiogenic potential of ERC in the hindlimb ischemia model, these data support a paradoxical tumor inhibitory activity of ERC. Further studies are needed to determine the qualitative differences between physiological angiogenesis, which seems to be supported by ERC and tumor angiogenesis which appeared to be inhibited.

KW - Cancer stem cells

KW - Endometrial regenerative cells

KW - Glioma

KW - Immune

KW - Mesenchymal stem cells

KW - Stem cell therapy

UR - http://www.scopus.com/inward/record.url?scp=61449183631&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=61449183631&partnerID=8YFLogxK

M3 - Article

C2 - 19197154

AN - SCOPUS:61449183631

VL - 8

SP - 606

EP - 610

JO - Cell Cycle

JF - Cell Cycle

SN - 1538-4101

IS - 4

ER -